Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2023-06-23 AGM Information
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
AGM Information Classification · 99% confidence The document is titled "Pherecydes Pharma communique les résultats de son Assemblée Générale Mixte du 23 juin 2023" (Pherecydes Pharma communicates the results of its Combined General Meeting of June 23, 2023). It explicitly details the approval of a merger between Pherecydes Pharma and Erytech Pharma during their respective General Meetings. The content focuses on shareholder votes, resolutions passed at the General Meeting, and the resulting corporate actions (merger completion, name change, stock listing changes). This directly relates to the outcomes of a shareholder meeting, making 'AGM Information' (AGM-R) the most appropriate classification, as it reports the results of the meeting.
2023-06-23 French
Inside Information / Other news releases
AGM Information Classification · 99% confidence The document is titled "Pherecydes Pharma announces the results of its Combined General Meeting of June 23, 2023." It explicitly details the approval of a merger between Pherecydes Pharma and Erytech Pharma by their respective shareholders during their Combined General Meetings (CGM). The text focuses on the voting outcomes, the effective date of the merger, and the resulting name change to Phaxiam Therapeutics. This content directly relates to the official results from shareholder votes at a general meeting. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-06-23 English
Inside Information / Other news releases
Legal Proceedings Report Classification · 99% confidence The document is a press release announcing a legal decision regarding a proposed merger between Pherecydes Pharma and Erytech Pharma. Key phrases include 'announced today', 'Press release', and the content focuses on litigation outcomes ('Commercial Court rejects Akkadian's request to postpone the merger vote') and the resulting shareholder vote date. This is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (PSI). Since it is a specific announcement regarding corporate action (merger litigation outcome) that doesn't fit perfectly into the other specific categories like M&A Activity (TAR) which usually covers the proposal itself, or a general regulatory filing (RNS), it is best classified as a Legal Proceedings Report (LTR) due to the central theme being the court ruling and associated legal costs/appointments. Given the context of a corporate action update, RNS is a possibility, but LTR is more precise for litigation news.
2023-06-14 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release dated June 14, 2023, announcing a legal decision by the Commercial Court of Lyon regarding a proposed merger between Pherecydes Pharma and Erytech Pharma. Specifically, it states that the court rejected Akkadian's request to postpone the shareholder vote on the merger scheduled for June 23, 2023. This content relates to a significant corporate action (merger/takeover bid) and the legal proceedings surrounding it. This fits best under 'M&A Activity' (TAR) as it directly concerns the progression of a merger proposal, or potentially 'Legal Proceedings Report' (LTR) due to the court ruling. Given the central theme is the merger vote proceeding despite legal challenges, TAR is the most specific fit, as it covers merger proposals. It is not a general regulatory filing (RNS) because it is highly specific to M&A.
2023-06-14 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated June 8, 2023, announcing that Pherecydes Pharma has submitted an application to the ANSM (French National Agency for the Safety of Medicines and Health Products) for authorization to conduct a Phase I clinical study for infectious endocarditis. This announcement details a specific corporate/scientific development (clinical trial submission) and is presented as a formal communication to the public and investors. It is not a full Annual Report (10-K), an Earnings Release (ER), a Call Transcript (CT), or a formal regulatory filing like a DVA or DIRS. Since it announces a significant corporate/scientific event and is structured as a press release, it best fits the general category of a Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the focus was purely on funding, but here the focus is on the clinical trial submission itself. Given the options, RNS serves as the best general category for significant, non-standard corporate announcements that don't fit the highly specific categories like ER, 10-K, or DIV. It is not a Report Publication Announcement (RPA) because it is the primary announcement of the event, not just an announcement that a report is available.
2023-06-08 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated June 8, 2023, announcing that Pherecydes Pharma has submitted an application to the ANSM (French regulatory body) for approval of a Phase I clinical study. It details the study's scope, endpoints, and expected timeline. This type of announcement, which communicates a significant operational or regulatory step (like filing for a clinical trial approval) but is not a formal financial report (like 10-K, IR, or ER), typically falls under general Regulatory Filings (RNS) or potentially Capital/Financing Update (CAP) if it were directly tied to fundraising, but here it is primarily a scientific/regulatory update. Since it is a specific announcement about a regulatory submission that doesn't fit the other specific categories (like M&A, Dividend, Director Dealing, etc.), the most appropriate general category is Regulatory Filings (RNS). It is not an Earnings Release (ER), Interim Report (IR), or a formal Audit Report (AR). It is too detailed to be a simple Report Publication Announcement (RPA).
2023-06-08 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.